06 Jun 2012, BioSpectrum Bureau , BioSpectrum
Singapore: Japanese company Mitsubishi Tanabe Pharma and Canada-based Cytochroma have terminated a license agreement executed in 2008.
The two companies have mutually agreed to the termination of a license agreement that granted Mitsubishi Tanabe an exclusive agreement to develop MT-2832 (lunacalcipol), a novel vitamin D compound, as a treatment for secondary hyperparathyroidism in dialysis patients.
Under the agreement, Mitsubishi Tanabe had license to MT-2832 in the US and Asia, including Japan. Upon termination of the agreement, Mitsubishi Tanabe will return the rights of MT-2832 to Cytochroma.